Early dopaminergic replacement treatment initiation benefits motor symptoms in patients with Parkinson's disease

被引:0
作者
Li, Xin [1 ,3 ]
Dong, Zhao-ying [2 ,3 ]
Dong, Meng [1 ]
Chen, Lei [3 ,4 ]
机构
[1] Tianjin Med Univ, Tianjin, Peoples R China
[2] Tianjin Peoples Hosp, Tianjin Union Med Ctr, Dept Neurol, Tianjin, Peoples R China
[3] Tianjin Huanhu Hosp, Dept Neurol, Tianjin, Peoples R China
[4] Tianjin Key Lab Cerebrovasc Dis & Neurodegenerat D, Tianjin, Peoples R China
来源
FRONTIERS IN HUMAN NEUROSCIENCE | 2024年 / 18卷
关键词
Parkinson's disease; motor symptoms; non-motor symptoms; dopaminergic replacement treatment; treatment initiation; DELAYED-START; LEVODOPA; PROGRESSION; PHARMACOTHERAPY; PRAMIPEXOLE; THERAPY;
D O I
10.3389/fnhum.2024.1325324
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Background: Parkinson's disease (PD) generally progresses slowly, but it is controversial whether delaying treatment accelerates the progression. Objective: Determine the correlation between the time of dopaminergic replacement treatment initiation and the severity of clinical symptoms in PD, including motor and non-motor symptoms. Methods: PD patients were divided between 155 people who were diagnosed de novo and 165 PD patients receiving dopamine replacement therapy. Basic patient characteristics included gender, age, age at onset, disease duration, and the time of dopaminergic replacement treatment initiation. We used MDS-UPDRS scores to evaluate the severity of motor symptoms and we also used the scale to assess the severity of non-motor symptoms such as cognition, mood, sleep, and quality of life. Results: The mean time between symptom onset and the initiation of drug treatment was 31.0 (22.5) months. After adjusting for age, sex, age at onset, and disease duration, we found that the MDS-Unified Parkinson's Disease Rating Scale (UPDRS)-III score increased faster in the de novo group with a similar disease duration (F = 8.7, p = 0.0034) than the treatment group. The cumulative incidence of progression to H-Y score 3 in de novo PD group over disease duration was 39.7% in 50months and 92.2% in 100 months, while in treated group such cumulative incidence was 15.5% in 50 months, 51.4% in 100 months and 81.5% in 150 months. The cumulative incidence of patients in the de novo PD group was higher than that in the treated group (p = 0.001), suggesting that untreated patients were more likely to progress to the advanced stages. Symptoms onset, the time between symptom onset and treatment initiation, age, sex, and disease duration explained 28.95% of the total variation in the MDS-UPDRS-III score for motor symptoms. In drug-na & iuml;ve patients, the time between symptom onset and treatment initiation explained 20.1% of the total variation in the MDS-UPDRS-III score for motor symptoms (t = 6.15, p < 0.001). Conclusions: These data in our study showed that early dopaminergic replacement treatment have played a positive role in PD patients, while dopaminergic replacement delayed treatment might be detrimental to motor symptoms and non-motor state of PD patient. Recognizing early stage symptoms of PD and early diagnosis are of great significance to treatment.
引用
收藏
页数:10
相关论文
共 50 条
  • [21] Influence of depressive symptoms on dopaminergic treatment of Parkinson's disease
    Hanganu, Alexandru
    Degroot, Clotilde
    Monchi, Oury
    Bedetti, Christophe
    Mejia-Constain, Beatriz
    Lafontaine, Anne-Louise
    Chouinard, Sylvain
    Bruneau, Marie-Andree
    [J]. FRONTIERS IN NEUROLOGY, 2014, 5
  • [22] Resting energy expenditure in Parkinson's disease patients under dopaminergic treatment
    Barichella, Michela
    Cereda, Emanuele
    Faierman, Samanta Andrea
    Piuri, Gabriele
    Bolliri, Carlotta
    Ferri, Valentina
    Cassani, Erica
    Vaccarella, Eleonora
    Donnarumma, Ornella Violetta
    Pinelli, Giovanna
    Caronni, Serena
    Pusani, Chiara
    Pezzoli, Gianni
    [J]. NUTRITIONAL NEUROSCIENCE, 2022, 25 (02) : 246 - 255
  • [23] Depressive symptoms and motor condition in Parkinson's disease patients
    Stella, F.
    Bucken-Gobbi, L. T.
    Gobbi, S.
    Sant'Ana-Simôes, C.
    [J]. REVISTA DE NEUROLOGIA, 2007, 45 (10) : 594 - 598
  • [24] Emerging Pharmacotherapies for Motor Symptoms in Parkinson's Disease
    Majali, Mohammad Al
    Sunnaa, Michael
    Chand, Pratap
    [J]. JOURNAL OF GERIATRIC PSYCHIATRY AND NEUROLOGY, 2021, 34 (04) : 263 - 273
  • [25] Non-Motor Symptoms in Treated and Untreated Chinese Patients with Early Parkinson's Disease
    Zhang, Hui
    Gu, Zhuqin
    An, Jing
    Wang, Chaodong
    Chan, Piu
    [J]. TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE, 2014, 232 (02) : 129 - 136
  • [26] Dopaminergic modulation of motor coordinaton in Parkinson's disease
    Park, Jaebum
    Lewis, Mechelle M.
    Huang, Xuemei
    Latash, Mark L.
    [J]. PARKINSONISM & RELATED DISORDERS, 2014, 20 (01) : 64 - 68
  • [27] Parkinson's disease patients with pain suffer from more severe non-motor symptoms
    Mao, Cheng-Jie
    Chen, Ju-Ping
    Zhang, Xiao-Yi
    Chen, Yi
    Li, Si-Jiao
    Li, Jie
    Xiong, Kang-Ping
    Hu, Wei-Dong
    Liu, Chun-Feng
    [J]. NEUROLOGICAL SCIENCES, 2015, 36 (02) : 263 - 268
  • [28] The impact of non-motor symptoms on the quality of life of Parkinson's disease patients: a longitudinal study
    Prakash, K. M.
    Nadkarni, N. V.
    Lye, W. -K.
    Yong, M. -H.
    Tan, E. -K.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2016, 23 (05) : 854 - 860
  • [29] Motor Complications of Dopaminergic Medications in Parkinson's Disease
    Freitas, Maria Eliza
    Hess, Christopher W.
    Fox, Susan H.
    [J]. SEMINARS IN NEUROLOGY, 2017, 37 (02) : 147 - 157
  • [30] Effects of dopaminergic replacement therapy on motor speech disorders in Parkinson's disease: longitudinal follow-up study on previously untreated patients
    Rusz, Jan
    Tykalova, Tereza
    Klempir, Jiri
    Cmejla, Roman
    Ruzicka, Evzen
    [J]. JOURNAL OF NEURAL TRANSMISSION, 2016, 123 (04) : 379 - 387